Skip to main content
Top
Published in: Breast Cancer Research 6/2002

01-12-2002 | Viewpoint

Mutations in DNA damage response genes and breast cancer susceptibility

Author: Robert B Clarke

Published in: Breast Cancer Research | Issue 6/2002

Login to get access

Excerpt

The risk of breast cancer is greatly increased in women who carry a mutation in one of the breast cancer susceptibility genes BRCA1 or 2. In the years since these genes were first isolated, evidence of their function in DNA damage responses and the DNA repair mechanism has accumulated. The DNA damage resulting from ionising and UV irradiation activates the ataxia-telangiectasia-mutated (ATM) and ataxia-telangiectasia- and RAD3-related (ATR) protein kinases, which in turn leads to the phosphorylation of BRCA proteins and other downstream targets such as CHEK2. It is known that the BRCA1 and 2 and CHEK2 gene products are cellular proteins that function to sense DNA damage, and to activate genes that both prevent cell cycle progression and initiate the DNA repair process. Several articles published over the last year have broadened our understanding of this pathway and its relevance to breast cancer risk and development. …
Literature
4.
6.
go back to reference Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr9_02.asp#meijers-heijboer CrossRefPubMed Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002, 31: 55-59. 10.1038/ng879. For the Faculty of 1000 evaluation of this article please see http://​breast-cancer-research.​com/​reports/​bcr9_​02.​asp#meijers-heijboer CrossRefPubMed
8.
go back to reference van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsey PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a. For the Faculty of 1000 evaluation of this article please see http://breast-cancer-research.com/reports/bcr9_02.asp#Veer CrossRefPubMed van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsey PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415: 530-536. 10.1038/415530a. For the Faculty of 1000 evaluation of this article please see http://​breast-cancer-research.​com/​reports/​bcr9_​02.​asp#Veer CrossRefPubMed
Metadata
Title
Mutations in DNA damage response genes and breast cancer susceptibility
Author
Robert B Clarke
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr549

Other articles of this Issue 6/2002

Breast Cancer Research 6/2002 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine